Alkermes Plc (ALKS) Receives $63.40 Average Price Target from Analysts

Alkermes Plc (NASDAQ:ALKS) has been given a consensus recommendation of “Hold” by the fifteen research firms that are currently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $64.09.

A number of research analysts recently issued reports on ALKS shares. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Citigroup set a $62.00 price target on Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th. BidaskClub raised Alkermes from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Credit Suisse Group decreased their price target on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, Barclays set a $50.00 price target on Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th.

Alkermes (NASDAQ:ALKS) traded down $2.33 during trading hours on Friday, reaching $53.67. The company had a trading volume of 584,623 shares, compared to its average volume of 929,528. The stock has a market capitalization of $8,250.00, a price-to-earnings ratio of -48.35 and a beta of 1.94. Alkermes has a 52-week low of $46.42 and a 52-week high of $64.04. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.

In other news, Director Paul J. Mitchell sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $56.77, for a total value of $56,770.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $510,930. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shane Cooke sold 1,700 shares of the business’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $60.02, for a total value of $102,034.00. Following the completion of the sale, the insider now directly owns 76,408 shares of the company’s stock, valued at $4,586,008.16. The disclosure for this sale can be found here. Insiders sold a total of 135,485 shares of company stock valued at $8,227,502 over the last three months. Company insiders own 5.34% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Toronto Dominion Bank increased its position in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after acquiring an additional 212 shares during the period. SG Americas Securities LLC acquired a new position in Alkermes in the 4th quarter valued at about $114,000. Quantbot Technologies LP acquired a new position in Alkermes in the 3rd quarter valued at about $126,000. Virtu Financial LLC acquired a new position in Alkermes in the 3rd quarter valued at about $201,000. Finally, M&T Bank Corp acquired a new position in Alkermes in the 4th quarter valued at about $221,000. 99.31% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Alkermes Plc (ALKS) Receives $63.40 Average Price Target from Analysts” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2018/02/16/alkermes-plc-alks-receives-63-40-average-price-target-from-analysts.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply